Head And Neck Squamous Cell Carcinoma

The addition of pembrolizumab to chemoradiotherapy demonstrated a trend toward longer EFS among patients with locally advanced head and neck squamous cell carcinoma, according to data presented at ESMO Congress.

A pembrolizumab-based regimen failed to significantly extend EFS among patients with unresected locally advanced head and neck squamous cell carcinoma, according to the agent’s manufacturer.

CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results presented at ASCO Annual Meeting.

DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.

DALLAS — Neoadjuvant immunotherapy did not increase risk for complications among patients who underwent surgery for head and neck cancers, according to study results presented at American Head & Neck Society Annual Meeting.

A phase 3 trial of nivolumab plus ipilimumab vs. the EXTREME regimen as first-line treatment of advanced squamous cell carcinoma of the head and neck failed to meet its primary endpoints of OS, according to a company-issued press release.

Two cycles of neoadjuvant pembrolizumab appeared safe and did not delay surgery among a cohort of patients with surgically resectable, locally advanced, HPV-negative head and neck squamous cell carcinoma, according to phase 2 study results.

The FDA approved a new cetuximab dosage regimen for the treatment of patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck, according to a press release.

April is Head and Neck Cancer Awareness Month.

The FDA granted breakthrough therapy designation to tipifarnib for treatment of certain patients with head and neck squamous cell carcinoma, according to the agent’s manufacturer.